微乳遞藥系統(tǒng)在紫杉烷類制劑中的應(yīng)用(編輯修改稿)
2025-01-15 15:05 本頁面
【文章內(nèi)容簡介】 dvantages Type I Oils without surfactants (. tri, diand monoglycerides) Nondispersing, requires digestion GRAS status。 simple。 excellent capsule patibility Formulation has poor solvent capacity unless drug is highly lipophilic Type II Oils and waterinsoluble surfactants SEDDS formed without watersoluble ponents Unlikely to lose solvent capacity on dispersion Turbid o/w dispersion (particle size –2 μm) Type III Oils, surfactants, cosolvents (both waterinsoluble and watersoluble excipients) SEDDS/SMEDDS formed with watersoluble ponents Clear or almost clear dispersion。 drug absorption without digestion Possible loss of solvent capacity on dispersion。 less easily digested Type IV Watersoluble surfactants and colsolvents (no oils) Formulation disperses typically to form a micellar solution Formulation has good solvent capacity for many drugs Likely loss of solvent capacity on dispersion。 may not be digestible 微乳遞藥系統(tǒng) 17 微乳在紫杉醇制劑中的應(yīng)用 ? 處方 – 三辛酸甘油酯一三丁酸甘油酯 – Cremophor EL – Poloxamer 188 – 蛋黃卵磷脂 – 乙醇 ? 10～ 50nm 微乳在紫杉烷制劑中的應(yīng)用 18 動物實(shí)驗(yàn) ? 過敏試驗(yàn) ? 藥動學(xué)評價 微乳在紫杉烷制劑中的應(yīng)用
規(guī)章制度相關(guān)推薦
鄂ICP備17016276號-1